-- On 26th Nov, 2020, Handian Pharma held an advisor board (AB) meeting on anti-COVID-19 Chinese herbal medicine “Handian Taishen Granule” in Ritan, Beijing. Handian Hongni Taishen Granule originates from the ancient formulation against taiyin cold-dampness disorder. This formula is of aromatic property and could dry dampness, resolve turbidity and dispel filthy pathogens. The research team of Handian Pharma has started screening and developing this innovative new drug since the fight against Ebola virus in 2015. The development of this product is based on epidemiological data, clinical usage, ancient dosing regimen and modern pharmaceutical technology in collaboration with professional and academic institutions including China Academy of Medical Sciences (CAMS), China Academy of Chinese Medical Sciences (CACMS) and GLP-certified bodies. Pharmacological, toxicological and clinical data are to be completed to further demonstrate its efficacy and safety. The company is also seeking for internal collaboration using this anti-viral Chinese herbal medicine.
Ritan Park used to be the sacred place to worship the God of Brightness-the sun. The AB meeting on Taishen Granule is held at this very location with the hope of this product acting like the sun to sweep away the umbrageous risk upon human’s lives, which is brought by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
COVID-19 is an infectious pandemic disease, belonging to “pestilence” in Traditional Chinese Medicine (TCM). It is caused by the contraction of pestilential toxin (SARS-CoV-2). Most of the COVID-19 patients are of cold-dampness constitutions. Exposure to this external cold-dampness pestilential toxin precipitates such patients to develop the TCM pattern of cold-dampness stagnating the lung.
This formula works by dispelling cold and dampness, adjusting the balance of yin and yang and regulating the taiyin cold-dampness constitution. It thus could act against the SARS-CoV-2, clearing the virus and preventing its transmission due to the residing cold-dampness environment of the patients, so as to counteract the damage to the body by the SARS-CoV-2.
In the morning, Handian Pharma（Group）invited several TCM experts including Prof. Chen Keji, academician of China Academy of Sciences, to this AB meeting. During the meeting, all participating experts praised highly of Taishen Granule. Preliminary clinical studies have already demonstrated its significant effect in the treatment of novel coronal pneumonia. This product is still undergoing preclinical studies. As there are very few current COVID-19 patients in China, the company plans to start collaborative clinical trials with overseas countries.
Major key opinion leaders and experts in the medical fields have participated this AB meeting, including Prof. Chen Keji, academician of China Academy of Sciences (CAS), Li Junde, deputy director of China Association of Chinese Medicine, Wang Xiaoliang, former director of Institute of Materia Medica, CAMS, Fang Dingya, Chief physician， former president of Xiyuan Hospital, CACMS, Liu Shuzhi, principal researcher of Institute of Chinese Materia Medica, CACMS.
Contact Info:
Name: Media Relations
Email: Send Email
Organization: Global News Online
Website: http://www.globalnewsonline.info
Source URL: www.globalnewsonline.info
Release ID: 88988957
Google
RSS